Leukocytosis Associated With Medroxyprogesterone in Gender-Affirming and Fertility Treatments.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: David Chu, Alexandros Konstantinidis, Garry G Lachhar, Fatimah Spall, Salman Syed

Ngôn ngữ: eng

Ký hiệu phân loại: 978.02 1800–1899

Thông tin xuất bản: United States : Cureus , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 684112

Leukocytosis, defined as an elevated white blood cell (WBC) count, can arise from physiological, infectious, neoplastic, or medication-related causes. While leukocytosis has been well-documented in conditions such as infections and malignancies, drug-induced leukocytosis is relatively rare, particularly in individuals undergoing gender transition therapies. Medroxyprogesterone, a progestin used in both fertility treatments and gender-affirming care, has been associated with hematologic changes, though its role in sustained leukocytosis remains underexplored. This case suggests a possible link between medroxyprogesterone and leukocytosis in gender-affirming therapy. It emphasizes the importance of thoroughly reviewing medication history to avoid unnecessary testing and procedures while highlighting the need for further research into the mechanism of progestin-induced hematologic changes.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH